

Simultaneous proteoglycans and hypoxia mapping of chondrosarcoma environment by frequency selective CEST MRI

Roxane Autissier, Leslie Mazuel, Elise Maubert, Jean-marie Bonny, Philippe Auzeloux, Sébastien Schmitt, Amidou Traoré, Caroline Peyrode, Elisabeth Miot-noirault, Guilhem Pagès

▶ To cite this version:

Roxane Autissier, Leslie Mazuel, Elise Maubert, Jean-marie Bonny, Philippe Auzeloux, et al.. Simultaneous proteoglycans and hypoxia mapping of chondrosarcoma environment by frequency selective CEST MRI. Magnetic Resonance in Medicine, In press, 86 (2), pp.1008-1018. 10.1002/mrm.28781. hal-03187913

HAL Id: hal-03187913 https://hal.science/hal-03187913

Submitted on 1 Apr 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



Simultaneous proteoglycans and hypoxia mapping of chondrosarcoma environment by frequency selective CEST MRI

Journal:	Magnetic Resonance in Medicine
Manuscript ID	MRM-20-21766.R1
Wiley - Manuscript type:	Full Paper
Research Type:	Physiological Research, Translational Research < Physiological Research
Research Focus:	Cancer, Pathology < Function < Cartilage < Musculoskeletal

SCHOLARONE[™] Manuscripts

1 ว		
2 3	1	Simultaneous proteoglycans and hypoxia mapping of chondrosarcoma environment
4 5	2	by frequency selective CEST MRI
6	3	Roxane Autissier ^{1,2,3} ; Leslie Mazuel ^{1,2,3} ; Elise Maubert ² ; Jean-Marie Bonny ^{1,3} ; Philippe Auzeloux ² ;
7 8	4	Sébastien Schmitt ² ; Amidou Traoré ^{1,3} ; Caroline Peyrode ² ; Elisabeth Miot-Noirault ² & Guilhem
9 10	5	Pagès ^{1,3}
10 11 12 13	6	
12 13	7	¹ INRAE, UR QuaPA, F-63122 Saint-Genès-Champanelle, France
14	8	² Université Clermont Auvergne, Inserm, IMoST, F-63000 Clermont-Ferrand, France
15 16	9	³ AgroResonance, INRAE, 2018. Nuclear Magnetic Resonance Facility for agronomy, food and health,
17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35	10	https://doi.org/10.15454/1.5572398324758228E12
	11	
	12	Correspondence: Roxane Autissier, PhD student
	13	UMR 1240 IMoST Inserm/Université Clermont Auvergne
	14	58, rue Montalembert, 63005 Clermont Ferrand cedex, France
	15	e-mail : Roxane.AUTISSIER@uca.fr
	16	
	17	Grant: Ligue Contre le Cancer Auvergne - Rhône - Alpes.
	18	
	19	Word count: 4201
	20	
	21	
36 37	22	
38		
39 40		
41		
42 43		
44 45		
46		
47 48		
49 50		
50 51		
52 53		
55 54		
55 56		
57		
58 59		
60		

23 ABSTRACT

Purpose: To evaluate the relevance of CEST frequency selectivity in simultaneous in vivo imaging of both of chondrosarcoma's (CHS) phenotypic features, i.e. its high proteoglycan (PG) concentration and its hypoxic core.

Methods: Swarm rat CHSs were implanted subcutaneously in NMRI Nude mice. When tumors were measurable (between 12 and 16 days post-operative), mice were submitted to GAG, guanidyl and amide proton transfer (APT) CEST imaging. PGs and hypoxia were assessed in parallel by nuclear imaging exploiting ^{99m}Tc-NTP 15-5 and ¹⁸F-FMISO, respectively. Data were completed by ex vivo analysis of PGs (histology and biochemical assay) and hypoxia (immunofluorescence).

Results: Quantitative analysis of GAG CEST evidenced a significantly higher signal for tumor tissues than for muscles. These results were in agreement with nuclear imaging and ex vivo data. For imaging tumoral pH in vivo, the CEST ratio of APT/Guanidyl was studied. It highlighted an important heterogeneity inside the tumor. The hypoxic status was confirmed by ¹⁸F-FMISO TEP imaging and ex vivo immunofluorescence.

Conclusion: CEST MRI simultaneously imaged both CHS properties during a single experimental run and without the injection of any contrast agent. Both MR and nuclear imaging as well as ex vivo data were in agreement and showed that this CHS animal model was rich in PGs. However, even if tumors were lightly hypoxic at the stage studied; acidic areas were highlighted and mapped inside the tumor.

ien

Keywords: CEST; Chondrosarcoma; Hypoxia; MRI; Nuclear imaging; Proteoglycans.

> Magnetic Resonance in Medicine

1. INTRODUCTION

Chondrosarcoma (CHS) is a malignant cartilaginous tumor representing the most common primary bone cancer in adults.^(1,2) CHS is characterized by a dense heterogeneous extracellular matrix (ECM), a low percentage of dividing cells and poor vascularity.⁽³⁾ The combination of these three factors leads to chemo and radiation therapy resistance.^(4–8)

Dense and fibrotic ECM with high levels of collagen and proteoglycans (PGs) is recognized to impair interstitial transport of drug from blood to cancer cells.⁽⁹⁾ In addition, the acidic microenvironment associated with hypoxia may electrostatically charge the drugs, limiting their ability to cross biological membranes.⁽¹⁰⁾ In vivo assessment of the phenotypic topological heterogeneity of the tumor microenvironment is key to optimizing personalized therapies. Although, biopsy is subject to sampling and pathologist/observer variability, microenvironmental characterization is mainly achieved from biopsy samples to determine grade and staging of the disease.⁽¹¹⁾ Tumor evaluation requires access to morphological and protein information in a context that takes into account intratumoral heterogeneity as a whole. In such a situation, developing imaging methods to access the main recognized CHS features, i.e. chondrogenic matrix and hypoxia, would be of great interest for diagnosis and clinical follow-up. Indeed, the current clinical imaging methods recommended, i.e. CT and MRI,⁽¹²⁾ are used to define tumor morphology and distinguish postoperative residues from postoperative or post-chemotherapeutic residual lesions. However, such approaches cannot be used in the same manner as functional imaging to assess tumor environment.⁽¹³⁾

Functional imaging can be done with specific radiotracers to access metabolic data useful to diagnose and assess the therapeutic response of CHS. Due to their rarity, there is a lack of large trials on functional imaging of chondroid tumors. Nowadays, nuclear medicine used to image CHS in a clinical context targets either the bone remodeling or the glucose tumoral metabolism with radiotracers such as ^{99m}Tc-MDP or ¹⁸F-FDG, respectively.⁽¹⁴⁾ To more accurately image the CHS microenvironment, radiotracers should target either ECM PGs or the CHS hypoxia feature. ^{99m}Tc-NTP 15-5 emerged from our lab as a candidate SPECT tracer for the functional imaging of cartilage by targeting PG negative charges in ECM. It demonstrated its relevance to specifically diagnose on CHS animal model and is expected to enter clinical trials shortly.⁽¹⁵⁻¹⁷⁾ One of the radiotracers extensively used in clinic for hypoxia is ¹⁸F-FMISO.⁽¹⁸⁾ As with many nitroimidazole derivatives, under reduced oxygen conditions, this tracer is reduced into a R-NO₂ radical that binds covalently to intracellular molecules leading ultimately to the entrapment of the tracer in hypoxic cells. To image both tumor features, two nuclear exams are required with two injections of radioactive contrast agent. Therefore, it would be interesting to develop a method to simultaneously image both of the metabolic properties of CHS.

The recent rise of CEST MRI has opened up new perspectives in the imaging of biological molecules within the tumoral microenvironment.⁽¹⁹⁾ This method is based on the exchange between saturated labile protons of the solute with the bulk water, revealing the endogenous contrast of some chemical functions. CEST MRI indirectly maps these low concentration metabolites by monitoring the variation of an

elevated water signal. Typically, a CEST experiment is a 2-step process. First, the magnetic field inhomogeneity has to be mapped; this is the function of the so-called water saturation shift referencing (WASSR) acquisition. Second, MR images must be recorded at several saturation frequency offsets to record a z-spectrum (normalized water signal as a function of the saturation offset for each voxel). This z-spectrum, with a zero-frequency referenced to the water's frequency will display an extra water attenuation at the metabolite exchangeable proton frequency, i.e. the CEST effect. To quantify this CEST effect, the first proposed method was based on the analysis of the water signal intensity at the offset of interest and its counterpart negative value. This magnetization transfer ratio asymmetry (MTRasym) analysis hypothesizes the absence of the magnetization transfer effect for negative offsets. As this hypotheses is not systematically verified, other z-spectrum analyses were developed, i.e. a three-offset measurement approach or multiple-pool Lorentzian fitting method.^(20,21) Hydroxyl, guanidyl and amide moieties were independently imaged by CEST MRI.^(22,23) Readers interested in a deeper explanation of CEST MRI principles are referred to the following references.⁽²⁴⁻²⁶⁾

CEST MRI has demonstrated its relevance for the quantitative evaluation and mapping of PGs in cartilaginous tissues by assessing the chemical exchange of saturable protons with the hydroxyl groups (i.e., around 0.5 - 1.5 ppm) of GAG molecules^(27,28) in both physiological and pathological situations.⁽²⁹⁻ ³¹⁾ In addition, CEST MRI has been demonstrated to be sensitive to pH variations, indirectly revealing information on the metabolic switch in response to hypoxia.⁽³²⁾ Several studies have demonstrated that pH variations impact the chemical exchange rate of both guanidyl and amide moieties.^(33,34) The change in the chemical exchange rate with the pH leads to a variation of the CEST intensity at frequencies of around 1.8 - 2.4 and 3.0 - 4.0 ppm for guanidyl and amide proton transfer (APT) CEST, respectively. Therefore, the combination of both guanidyl and APT CEST has been proposed as a highly sensitive method to explore extracellular pH acidification in tumors.^(35,36)

104 Considering that PGs and pH each have their own resonance frequencies, and are therefore sensitive 105 to different exchangeable moieties, we decided these two features would merit further study using a 106 single CEST MRI acquisition on CHS animal model. The aim of this study was to evaluate the relevance 107 of frequency-selected CEST MRI to simultaneously map PG concentration and pH of CHS tissue in 108 vivo. To validate this approach, CEST MRI was compared to the standard reference nuclear imaging as 109 well as ex vivo analysis.

111 2. METHODS

2.1. GAG and pH phantom experiments

Phosphate-buffered saline (PBS) 1X (Gibco Laboratories, Gaithersburg, MD, USA) containing 1% of bovine serum albumin (BSA) solution (Sigma Aldrich, St. Louis, MO, USA) was used to prepare the chondroitin 4-sulfate phantom. Five samples of the chondroitin 4-sulfate (Sigma Aldrich, St. Louis, MO, USA) were prepared at. 1; 5; 10; 20; 40 mg/mL at pH 7.4. For protamine phantom, 15 mg/mL of protamine (Sigma Aldrich, St. Louis, MO, USA) and 0.15 mM of MnCl₂ were dissolved in PBS. Four

Page 5 of 44

118 samples of protamine were prepared with pH ranging from 6.5 to 7.7 in 0.4 unit increments. Both 119 phantoms (chondroitin 4-sulfate and protamine) were prepared with 15 % gelatin in water to fix the 120 syringes containing the different solutions. Phantoms were submitted to the same acquisition and 121 analysis protocols as described below except for B_1 , which was set to 3 μ T.

2.2. Xenograft model of SWARM rat CHS

Experiments were conducted in accordance with the European directive 2010/63/EU after approval
by the animal ethical committee C2E2A, authorization number: #15991.

SWARM rat CHS (SRC) xenografts were performed in 5 week old female NMRI Nude immunodeficient mice (Janvier Labs, Le Genest-Saint-Isle, FR) from frozen fragments after reactivation in 4 week old male Sprague Dawley rats (Charles River Laboratories France, Saint Germain Nuelles, FR). For reactivation, SRC fragments were defrosted in Dulbecco's Modified Eagle Medium (DMEM, Gibco Laboratories, Gaithersburg, MD, USA) then implanted subcutaneously on the right flank of 3 anesthetized rats (isoflurane; 2.5 %, 1 L/min, air/O₂, 70/30, v/v). After 22 days post-surgery, tumors were resected and immediately placed in cold DMEM. Then, they were manually calibrated to 1 mm³ and transplanted subcutaneously between the shoulder blades on anesthetized (isoflurane; 1.5 %, 1 L/min, air/O2, 70/30, v/v) NMRI Nude immunodeficient mice (n=10) and cutaneous wounds were sutured.

2.3. In vivo animal imaging

All imaging experiments were performed at "In Vivo Imaging in Auvergne" (IVIA) facility (https://doi.org/10.18145/ivia). Imaging protocols were performed on the same mice between 12 and 16 days after induction, corresponding to an average tumoral volume of $215.04 \pm 86.28 \text{ mm}^3$ (see supporting Figure S1). During these in vivo acquisitions, all animals were anesthetized by isoflurane (1.5 %, 1 L/min, air/O₂, 70/30, v/v). All animals were secured on a dedicated bed with both breathing rate and temperature being monitored during acquisitions. Supporting Table S1 describes in details the animal distribution for each imaging modality.

46 145 47 146

2.3.1.MR imaging

MR images of mice (n = 10) were acquired on an 11.7 Tesla Bruker BioSpec system (Bruker
BioSpin, Ettlingen, Germany) piloted by Paravision 6.0.1 software. A 72 mm circular polarizer volume
coil was used for RF transmission and a surface array coil (2x2) positioned on both the tumor and the
adjacent muscle received the NMR signal (Bruker BioSpin, Ettlingen, Germany).

55
56151*DW imaging:* Tumor imaging was performed with a DWI sequence (b=500 s.mm⁻², direction56
57152[0,0,1]) with a TE of 27 ms and a TR of 2000 ms. The FOV was 40 mm with an axial slice thickness of58
591531 mm leading to a nominal resolution of $0.26 \times 0.26 \times 1 \text{ mm}^3$. The number of slices was adjusted to

image the whole tumor (generally, 12 slices were needed). Two averages were performed for a total acquisition time of 7 min 32 s.

CEST Imaging: CEST acquisitions were based on a RARE sequence with an effective TE and TR of 4.756 and 4500 ms, respectively and a RARE acceleration factor of 16. The slice thickness was 2 mm and the FOV 40 mm, i.e. the in-plane voxel size was 0.625×0.625 mm². Each image was recorded from a single transient. A first z-spectrum was recorded to correct for B_0 inhomogeneities by using the WASSR approach⁽³⁷⁾ (saturation pulses $B_1 0.1 \mu T$, 54.8 ms gaussian pulses repeated 18 times with an interpulse delay of a 0.010 ms, and a bandwidth of 20 Hz leading to a train of 1 s; saturation offsets from \pm 1000 Hz with $\Delta \omega$ 20 Hz) followed by the CEST z-spectrum (30 min acquisition duration with saturation pulses: B_1 1.5 μ T, 54.8 ms gaussian pulses repeated 72 times with a bandwidth of 50 Hz leading to a train of 4 s and an equivalent continuous wave CEST saturation of $0.6 \,\mu$ T; saturation offsets from ± 2500 Hz with $\Delta \omega$ 50 Hz). CEST MRI data were analyzed with an in-house program written in MATLAB® R2017a (MathWorks, Natick, MA USA). In brief, a ROI was manually drawn on the high-resolution DW image to delineate the tumor and muscle of the scapular region. Then, B_0 shift was corrected pixel-by-pixel with the WASSR approach. Finally, the CEST methodology applied to analyze the data depended on the saturation offset. For GAG CEST, the analysis was performed on the whole image and the z-spectrum was fitted with two Lorentzian shapes: the first one to estimate the signal attenuation due to the water direct saturation (centered at 0 ppm) and the second one for the hydroxyl moieties. The GAG CEST signal intensity corresponded to the area of this latter Lorentzian shape. Regarding guanidyl and APT CEST, we applied the three-offset measurement approach proposed by Jin et al.⁽²⁰⁾ to avoid nuclear overhauser enhancement (NOE) interferences. In practice, two limits were chosen (1.60 to 2.40 and 3.20 to 4.00 ppm for the guanidyl and amide moieties, respectively) and a baseline was drawn between these frequencies. The CEST effect for APT* and guanidyl* were quantified as the difference between the baseline and the water signal at 1.96 and 3.68 ppm, respectively. The ratio of APT*/guanidyl* was then calculated. The relative variation of this ratio was expressed from the mean ratio value on the ROI.

2.3.2. Nuclear Imaging

PGs imaging by SPECT/CT using 99mTc-NTP 15-5 radiotracer: SPECT-CT images were acquired using a camera (NanoScan[®], Mediso Ltd, Budapest, Hungary) equipped with four multi pinhole detectors APT62. Acquisitions were performed on Nucline software (v3.00.018, Mediso Ltd, Budapest, Hungary). 20 MBq of ^{99m}Tc-NTP 15-5, radiolabeled as described ⁽³⁸⁾, were injected intravenously in the tail vein. After 30 min, mice (n = 10) were anesthetized and imaged. Anatomic CT acquisition consisted of a helical scan with 480 projections, 300 ms per projection, 50 kV, 590 µA. Then, SPECT images were performed with 128 projections, 20 s per projection and an energy window set at 140 keV \pm 20 %. After image reconstructions using the 3D ordered subset expectation maximization (3D OSEM) algorithm, analyses were performed with InterviewTMFUSION (v3.03.074, Mediso Ltd, Budapest,

Hungary) software using an interpolated ellipse ROI for both tumor and scapular muscle manuallydrawn slice by slice. Activity concentrations were obtained in kBq/mL.

Hypoxia PET imaging using ¹⁸F-FMISO: PET images were acquired using a small animal device (eXplore Vista[®], GE Healthcare, Chicago, IL, USA). 30 MBq of ¹⁸F-FMISO were injected intravenously in the tail vein. Four hours later, the mice (n = 10) were anesthetized and PET imaging was performed with a 250 to 700 keV energy window and 6 ns coincidence time window (30 min duration, 2 bed positions) with MMWKS® Image software (GE Healthcare, Chicago, IL, USA). After 2D OSEM reconstructions, analyses were performed with VivoQuantTM (v4.0 patch1, inviCRO, Boston, MA, USA) software using a 3D ROI for tumor and scapular muscle manually drawn. ¹⁸F-FMISO uptake was quantified in kBq/mL.

2.4. Ex vivo analysis

Histological and immunofluorescence analysis in tumoral tissues were performed at the
 histopathology facility ANIPATH (CNRS UMR 6293 / Inserm U1103 GReD, Clermont-Ferrand, FR).

After a multimodal imaging session, 20 days post-induction, mice (n = 3) were sacrificed by cervical dislocation under anesthesia and tumors were resected and cut into two samples. The first sample was fixed into 10 % neutral buffered formalin for 24 h and embedded in paraffin for histological analysis (alcian blue or pimonidazole staining). The second sample was frozen in liquid nitrogen for GAG assays. For pimonidazole analysis, animals received an intraperitoneal injection of pimonidazole hydrochloride (60 mg/kg, HypoxyprobeTM, Burlington, MA, USA) 1 hour before sacrifice.

Alcian blue staining: 5 µm thick sections of embedded tumors were cut and adhered to poly-LLysine-coated microscope slides. After dewaxing and rehydration, slides were stained by Alcian blue
(pH 1) to visualize PGs, counterstained by nuclear red after which coverslips were fixed. Staining was
detected and images were recorded using a slide scanner (X20, Zeiss AxioScan Z1, ZEN software).

Pimonidazole staining: 5 µm thick sections of embedded tumors were cut and adhered to poly-L-Lysine-coated microscope slides. After dewaxing and rehydration of tumor slices, antigens were retrieved (boiling tris: 10 mM, pH 6) and slides were placed into the InsituPro VSi robot (Intavis bioanalytical instruments, Köln, Germany). Endogenous peroxidases were quenched (H₂O₂: 0.3 %, 30 min) and saturated (BSA: 1 %, 1 h). Slides were then incubated with a primary antibody (anti-pimonidazole: mouse monoclonal antibody, 1/300, 1h, RT; HypoxyprobeTM). Biotinylated secondary antibody (1/500, BSA 0.1 %, 1 h; Vector Laboratories) was used to reveal the first antibody. Biotin was then complexed with streptavidin-coupled horseradish peroxidase (HRP) (1/500, 30 min; Vector Laboratories). Peroxidase was detected using tyramide signal amplification (TSA) as per manufacturer's instructions (TSA-Alexa488; InvitrogenTM). Then, nuclei were counterstained with Hoechst (33342) and coverslips were fixed. Emitted fluorescences (461 nm for Hoechst and 519 nm for TSA) were imaged and recorded as previously (X20, Zeiss AxioScan Z1, ZEN software, Oberkochen, Germany).

GAG assay: samples (n=10) were weighed (20-50 mg) and incubated overnight at 65°C in 1 mL of
a papain extraction buffer and then centrifuged (1000 g, 10 min). Sulfated GAG content was determined
using a Blyscan® Sulfated Glycosaminoglycan assay kit (Biocolor Ltd, Carrickfergus, UK) as per
manufacturer's instructions. Absorbance was measured at 656 nm using Thermo Scientific Multiskan
GO device (Thermo Fisher Scientific, Waltham, MA, USA). Experiments were performed in duplicates.

2.5. Statistical analyses

Statistical analyses were performed on Prism software version 6.0 (GraphPad Software, San Diego, CA, USA). For in vivo and ex vivo studies, data were presented as individual values with mean \pm SD. Data normal distributions were verified with Shapiro-Wilk tests before performing Student's *t*-tests. For in vivo imaging quantification, paired Student's *t*-tests were applied and for ex vivo analyses, unpaired Student's *t*-tests were performed. Results were considered significant at P < 0.05 (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Significance of results was verified with a Wilcoxon matched-pairs signed rank test.

3. RESULTS

3.1. GAG, guanidyl and APT CEST on phantoms

GAG CEST effects were observed on the z-spectra of chondroitin 4-sulfate solutions (Figure 1A) and guanidyl and APT CEST effects on that of protamine solutions (Figure 1C). The highest CEST effect offset for each moiety appeared at different chemical shifts: 0.75, 1.96 and 3.68 ppm for GAGs, guanidyl and APT, respectively.

Linear relationships were found between CEST AUCs and either the GAG concentration ($R^2=0.9845$) or the pH ($R^2=0.8849$ and $R^2=0.8477$, for Guanidyl* and APT* respectively). An increase in GAG concentration and in pH led to an increase of the CEST signal (Figure 1B, 1D). The relative variation of the ratio (reference pH at 7.2) increased from pH 6.8 to 7.7.

Figure 1 appears near here

3.2. Quantitative assessment of GAGs in CHS tumoral tissue

From signal analysis of GAGs by CEST MRI, a GAG concentration-related map (Figure 2A) was constructed. The signal from GAG was clearly evidenced within tumoral tissue, and was observed to be heterogeneously distributed. Regarding muscle, CEST MRI of GAGs was very low with AUC =2.15 \pm 1.88 as compared to 27.29 \pm 8.38 in tumor (*P* < 0.0001; n=9) (Figure 2B) leading to a tumor/muscle ratio of 23.35 \pm 16.97

55
56260Nuclear imaging, evidenced a significantly (P < 0.0001; n=9) higher uptake of the 99m Tc-NTP 15-557261radiotracer in tumoral tissue (179.38 ± 38.39 kBq/mL) as opposed to muscle (35.07 ± 5.17 kBq/mL),58
59262leading to a tumor/muscle ratio of 5.11 ± 0.69 (Figure 2C and 2D). Four images of 99m Tc-NTP 15-560263SPECT imaging are shown on supporting Figure S3A.

Page 9 of 44

1

2	
3	264
4 5	265
6 7	266
8	267
9 10	268
11	269
12 13	270
14 15	271
15 16	272
17 18	273
19	274
20 21	275
22	276
23 24	277
25 26	278
20 27	279
28 29	280
30	281
31 32	282
33	283
34 35	284
36 37	285
38	286
39 40	287
41	288
42 43	289
44 45	290
45 46	291
47 48	292
49	293
50 51	294
52	295
53 54	296
55 56	297
57	298
58 59	299
60	300

Ex vivo experiments confirmed this high PG feature of CHS tissue. From biochemical assays, GAG concentration was demonstrated to be $6.33 \pm 1.60 \ \mu\text{g/mg}$ in the tumor while it was only $0.41 \pm 0.09 \ \mu\text{g/mg}$ in the muscle (*P* < 0.0001) (Figure 2F). As illustrated on figure 2E, tumoral tissue was strongly stained by alcian blue confirming its richness in GAGs.

Figure 2 appears near here

3.3. Quantitative assessment of pH and hypoxia in CHS tumoral tissue

Figures 3A shows both the anatomical and relative variation of the APT*/guanidyl* ratio images for 3 randomly chosen mice out of 7. The ratio was only calculated inside the tumor as it cannot be compared with muscle due to extra CEST signal coming from creatine and phosphocreatine. The CESTbased images highlighted a heterogeneous pH distribution inside the tumor.

Figure 3B displays a representative image of ¹⁸F-FMISO PET. While on this slice, a clear difference between the tumor and the muscle was observed, this was no longer the case once the signal was integrated over the whole tumor (red dots on Figure 3C). At the group level (n=5), the tumor mean signal (18.70 \pm 10.54 kBq/mL) was different from the muscle's signal (8.60 \pm 4.30 kBq/mL). However, the inter-individual variations, especially for the tumor, led to the absence of differences between both tissues. The three incidences of ¹⁸F-FMISO PET imaging are shown on supporting Figure S3B.

Ex vivo experiments by immunofluorescence with pimonidazole evidenced a weak staining within tumoral tissue, mainly localized in the center of CHS lobules (Figure 3D).

Figure 3 appears near here

4. DISCUSSION

86 This work aimed to develop in one-scan multiple CEST MRI contrasts to characterize in vivo PG and hypoxic features of the CHS microenvironment. By exploiting the CEST frequency selectivity, we 87 aimed to simultaneously image the PG concentration and pH as it relates to hypoxia. CEST MRI images 88 89 were compared to current state of the art imaging approaches, i.e. ^{99m}Tc-NTP 15-5 and ¹⁸F-FMISO to 90 map PGs and hypoxia, respectively. To our knowledge, this work is the first one to investigate the 91 microenvironment of CHS by CEST MRI. In most published studies exploiting CEST MRI to image 92 GAG concentration and pH, different saturation protocols are used. Both level and duration of the saturation RF trains are optimized depending on the exchangeable protons targeted. Typically, to image 93 the hydroxyl moieties, the saturation pulse level is moderate while the duration is long.^(39,40) For APT 94 CEST, a variety of saturation conditions have been used.⁽⁴¹⁾ However, to maximize the APT effect, Zhou 95 et al.⁽⁴¹⁾ recommend the usage of a saturation duration higher than 0.8 s and a level of around 2 μ T. Our 96 experimental conditions were close to the optimal ones for the different contrasts. As we wanted to 97 image both tumor features in a single acquisition, we chose to use a long saturation train $(t_{sat}=4 \text{ s})$ with 98 moderate power ($B_1=1.5 \mu T$) that was demonstrated from phantom experiments to be a satisfactory 99 300 compromise. Indeed, the GAG CEST effect was not too broad and did not overlap with the guanidyl

one. Obviously, this compromise on the saturation parameters is at the cost of the optimized sensitivity for each CEST effect. Carefully choosing the saturation frequencies made it possible to simultaneously assess PGs (GAG CEST) and pH (guanidyl and APT CEST). In vitro, we can note that we found an increase of the guanidyl* signal like Oskolkov et al.⁽⁴²⁾ while Jin et al.⁽³⁴⁾ observed an opposite trend. This discrepancy can be due to (i) our multiple-contrast CEST conditions, experimental conditions were not set to the optimal values to maximize the CEST effect for pH, (ii) physical parameters, especially the chemical exchange rate constant, are not comparable to what was simulated in the other study. To obtain a pH variation independent of protein concentration, the ratio of the APT* and guanidyl* CEST was calculated.

In vivo GAG CEST images were obtained by acquiring signals resulting from the chemical exchange of the abundant hydroxyl groups in GAGs. A 23 times higher CEST effect was observed for the tumor compared to muscle demonstrating the high PG density in the CHS microenvironment. CEST signal studies of different forms of GAGs typically found in articular cartilage recently demonstrated that the CEST effect arises mainly from chondroitin 4-sulfate.⁽⁴³⁾ SRC was demonstrated to highly express aggrecan which is composed of a core protein with covalently attached side chains of linear GAGs, including a high number of chondroitin sulfate, especially chondroitin 4-sulfate.⁽⁴⁴⁾ The GAG CEST approach was combined with ^{99m}Tc-NTP 15-5 nuclear imaging, a radiotracer designed to target negatively charged molecules of GAGs.^(16,45) As expected, a higher radiotracer accumulation was observed in tumor in respect to muscle (ratio ~5), confirming the higher PG concentration measured by GAG CEST. The discrepancies in the tumor to muscle ratios between the MRI and nuclear imaging can be explained by the poor vascularization of the tumor, thereby limiting the delivery of the radiotracer. Since CEST MRI provided signals from hydroxyl moieties of PGs, we also have to consider that hydroxyl moieties are found in other molecules such as glucose or lactate.^(46,47) We therefore were interested to complete GAG CEST with ¹H MRS to identify their respective contribution in the CEST signal. Unfortunately, due to its high chondrogenic structure, CHS tissue did not provide enough resolution on the MRS spectrum. Finally, ex vivo quantitative analysis, i.e. GAG assays, reinforced the in vivo multimodal imaging results and evidenced high PG concentration within tumoral tissue (ratio tumor/muscle ~18, i.e. in between SPECT and CEST ratios).

CEST MRI assessment of intratumoral pH variations was performed by exploiting both guanidyl and amide to enhance the sensitivity of pH weighted MRI.⁽³⁴⁾ As acidosis is associated to hypoxia⁽⁴⁸⁾, it was expected that mapping tumoral pH through CEST MRI would be a relevant methodology to delineate areas of hypoxic and well oxygenated cells within tumoral tissue. The CEST signals from both chemical groups were assigned to proteins. To have a map independent from protein concentration, the APT*/guanidyl* ratio was calculated inside the tumor. This approach assumes that the guanidyl signal is coming only from the proteins. This hypothesis is acceptable for tumors, although it cannot be applied to other tissues, especially muscle, due to the presence of creatine and phosphocreatine. These metabolites give a guanidyl signal, the APT*/guanidyl* ratio will depend on both pH and the metabolite

concentrations. In vivo ¹⁸F-FMISO PET imaging confirmed the hypoxic status of CHS since the mean tumor/muscle ratio value was approximately 2. However, at the group level there was no statistical difference between the two tissues due to large inter-individual variations. Ex vivo immunofluorescence with pimonidazole evidenced that hypoxic areas were heterogeneously distributed throughout the tumoral tissue similarly to CEST MRI.

The assessment of pH by APT CEST is debated in the literature. Some authors reported a decrease of the CEST effect on the pH (49,50) while others observed the opposite. (51,52) Most of these APT CEST effects were obtained after performing the so-called MTR_{asym} analysis. The key assumption in this data processing is that for negative offsets, only the direct water saturation effect is recorded.⁽⁵³⁾ However, it was shown in vivo that several NOE exchanges were recorded in the region of \sim -1 to -4 ppm, no longer fulfilling the MTR_{asym} assumption.⁽⁵⁴⁾ Nevertheless, most of these studies used this estimator. To avoid the interference of the NOE on our CEST quantifications, our data were analyzed by using the approach inspired by Jin et al.⁽²⁰⁾ and described in section 2.3.1.

To conclude, our work on SRC bearing mice demonstrated the potential of imaging the different tumoral microenvironment properties by a single CEST MRI acquisition. MRI presents the main advantage when compared to nuclear imaging to give high-resolution spatial information. It is then possible to delineate accurately the metabolism-related region of interest. Such parametric maps would allow a better understanding of the relationship between tumor cells and their environment, thus becoming a prerequisite to develop more individualized therapies.

ACKNOWLEDGEMENTS The authors thank Christelle Damon-Soubeyrand (Anipath facility) for her precious technical help with histological equipment.

REFERENCES

- Key Statistics for Bone Cancer: Key Statistics About Bone Cancer. American Cancer Society 1. Web site. https://www.cancer.org/cancer/bone-cancer/about/key-statistics.html. Updated January 12, 2021. Accessed January 22, 2021.
- World Health Organization WHO, Fletcher C, Bridge JA, Hogendoorn PCW, Mertens F. WHO 2. Classification of Tumours of Soft Tissue and Bone. In: WHO Classification of Tumours, vol. 5. 4th ed. World Health Organization; 2013. p 264-268.
- Gelderblom H, Hogendoorn PCW, Dijkstra SD, et al. The clinical approach towards 3. chondrosarcoma. Oncologist. 2008;13(3):320-329.
- Mery B, Espenel S, Guy J-B, et al. Biological aspects of chondrosarcoma: Leaps and hurdles. 4. Crit Rev Oncol Hemat. 2018;126.
- 5. Angelini A, Guerra G, Mavrogenis AF, Pala E, Picci P, Ruggieri P. Clinical outcome of central conventional chondrosarcoma. J Surg Oncol. 2012;106(8):929-937.

1 ว			
2 3	374	6.	van Oosterwijk JG, Anninga JK, Gelderblom H, Cleton-Jansen A-M, Bovée JVMG. Update on
4 5	375		targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma. Hematol
6	376		Oncol Clin North Am. 2013;27(5):1021-1048.
/ 8	377	7.	Nazeri E, Gouran Savadkoohi M, Majidzadeh-A K, Esmaeili R. Chondrosarcoma: An overview
9 10	378		of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic
11	379		targets. Crit Rev Oncol Hematol. 2018;131:102-109.
12 13	380	8.	Yeldag G, Rice A, Del Río Hernández A. Chemoresistance and the self-maintaining tumor
14	381		microenvironment. Cancers (Basel). 2018;10(12):471.
15 16	382	9.	Davies C de L, Berk DA, Pluen A, Jain RK. Comparison of IgG diffusion and extracellular
17 18	383		matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals
19	384		the role of host stromal cells. Br J Cancer. 2002;86(10):1639-1644.
20 21	385	10.	Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor
22	386		microenvironment. J Natl Cancer Inst. 2007;99(19):1441-1454.
23 24	387	11.	Skeletal Lesions Interobserver Correlation among Expert Diagnosticians (SLICED) Study
25 26	388		Group. Reliability of histopathologic and radiologic grading of cartilaginous neoplasms in long
27	389		bones. J Bone Joint Surg Am. 2007;89(10):2113-2123.
28 29	390	12.	Murphey MD, Walker EA, Wilson AJ, Kransdorf MJ, Temple HT, Gannon FH. From the
30	391		archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation.
31	392		Radiographics. 2003;23(5):1245-1278.
33 34	393	13.	Logie CI, Walker EA, Forsberg JA, Potter BK, Murphey MD. Chondrosarcoma: A diagnostic
35	394		imager's guide to decision making and patient management. Semin Musculoskelet Radiol.
36 37	395		2013;17(2):101-115.
38	396	14.	Jo I, Gould D, Schlicht S, Taubman K, Choong P. Diagnostic accuracy of functional imaging
39 40	397		modalities for chondrosarcoma: A systematic review and meta-analysis. J Bone Oncol.
41 42	398		2019;19:100262.
43	399	15.	Miot-Noirault E, Gouin F, Vidal A, et al. First preclinical imaging of primary cartilage neoplasm
44 45	400		and its local recurrence using 99mTc-NTP 15-5 radiotracer. J Nucl Med. 2009;50(9):1541-1547.
46	401	16.	Peyrode C, Gouin F, Vidal A, et al. A"Proteoglycan targeting strategy" for the scintigraphic
47 48	402		imaging and monitoring of the swarm rat chondrosarcoma orthotopic model. Sarcoma.
49 50	403		2011;2011:691608.
51	404	17.	Miot-Noirault E, Vidal A, Auzeloux P, Peyrode C, Madelmont J-C, Chezal J-M. In vivo
52 53	405		scintigraphic imaging of proteoglycans. Methods Mol Biol. 2012;836:183-198.
54	406	18.	Rajendran JG, Mankoff DA, O'Sullivan F, et al. Hypoxia and glucose metabolism in malignant
55 56	407		tumors: Evaluation by [18F]Fluoromisonidazole and [18F]Fluorodeoxyglucose positron
57	408		emission tomography imaging. Clin Cancer Res. 2004;10(7):2245-2252.
оө 59	409	19.	Goldenberg JM, Pagel MD. Assessments of tumor metabolism with CEST MRI. NMR Biomed.
60	410		2019;32(10):e3943.

1			
2 3	411	20.	Jin T, Wang P, Zong X, Kim S-G. MR imaging of the Amide-Proton Transfer effect and the pH-
4 5	412		insensitive Nuclear Overhauser Effect at 9.4 T. Magn Reson Med. 2013;69(3):760-770.
6	413	21.	Zhou Y, van Zijl PCM, Xu X, et al. Magnetic resonance imaging of glycogen using its magnetic
/ 8	414		coupling with water. Proc Natl Acad Sci USA. 2020;117(6):3144-3149.
9 10	415	22.	Jones KM, Pollard AC, Pagel MD. Clinical applications of chemical exchange saturation transfer
11	416		(CEST) MRI. J Magn Reson Imaging. 2018;47(1):11-27.
12 13	417	23.	Kogan F, Hariharan H, Reddy R. Chemical Exchange Saturation Transfer (CEST) imaging:
14	418		Description of technique and potential clinical applications. Curr Radiol Rep. 2013;1(2):102-
15 16	419		114.
17 18	420	24.	van Zijl PCM, Yadav NN. Chemical Exchange Saturation Transfer (CEST): what is in a name
19	421		and what isn't? Magn Reson Med. 2011;65(4):927-948.
20 21	422	25.	Wu B, Warnock G, Zaiss M, et al. An overview of CEST MRI for non-MR physicists. <i>EJNMMI</i>
22	423		<i>Phys.</i> 2016;3(1):19.
23 24	424	26.	Dou W, Lin C-YE, Ding H, et al. Chemical exchange saturation transfer magnetic resonance
25 26	425		imaging and its main and potential applications in pre-clinical and clinical studies. Quant
27	426		Imaging Med Surg. 2019;9(10):1747-1766.
28 29	427	27.	Ling W, Regatte RR, Navon G, Jerschow A. Assessment of glycosaminoglycan concentration in
30 21	428		vivo by chemical exchange-dependent saturation transfer (gagCEST). Proc Natl Acad Sci USA.
32	429		2008;105(7):2266-2270.
33 34	430	28.	Brinkhof S, Nizak R, Khlebnikov V, Prompers JJ, Klomp DWJ, Saris DBF. Detection of early
35	431		cartilage damage: feasibility and potential of gagCEST imaging at 7T. Eur Radiol.
36 37	432		2018;28(7):2874-2881.
38	433	29.	Krusche-Mandl I, Schmitt B, Zak L, et al. Long-term results 8 years after autologous
39 40	434		osteochondral transplantation: 7 T gagCEST and sodium magnetic resonance imaging with
41 42	435		morphological and clinical correlation. Osteoarthr Cartil. 2012;20(5):357-363.
43	436	30.	Krishnamoorthy G, Nanga RPR, Bagga P, Hariharan H, Reddy R. High Quality 3D gagCEST
44 45	437		Imaging of In Vivo Human Knee Cartilage at 7T. Magn Reson Med. 2017;77(5):1866-1873.
46 47	438	31.	Wei W, Lambach B, Jia G, Kaeding C, Flanigan D, Knopp MV. A Phase I clinical trial of the
47 48	439		knee to assess the correlation of gagCEST MRI, delayed gadolinium-enhanced MRI of cartilage
49 50	440		and T2 mapping. Eur J Radiol. 2017;90:220-224.
51	441	32.	Corbet C, Feron O. Tumour acidosis: from the passenger to the driver's seat. Nat Rev Cancer.
52 53	442		2017;17(10):577-593.
54	443	33.	Chen LQ, Pagel MD. Evaluating pH in the extracellular tumor microenvironment using CEST
55 56	444		MRI and other imaging methods. Adv Radiol. 2015;2015:1-25.
57 58	445	34.	Jin T, Wang P, Hitchens TK, Kim S-G. Enhancing sensitivity of pH-weighted MRI with
59 60	446		combination of amide and guanidyl CEST. <i>Neuroimage</i> . 2017;157:341-350.

2			
3 4	447	35.	Maloney E, Wang Y-N, Vohra R, et al. Magnetic resonance imaging biomarkers for pulsed
5	448		focused ultrasound treatment of pancreatic ductal adenocarcinoma. World J Gastroenterol.
6 7	449		2020;26(9):904-917.
8	450	36.	Loi L, Zimmermann F, Goerke S, et al. Relaxation-compensated CEST (chemical exchange
9 10	451		saturation transfer) imaging in breast cancer diagnostics at 7T. Eur J Radiol. 2020;129:109068.
11 12	452	37.	Kim M, Gillen J, Landman BA, Zhou J, van Zijl PCM. Water saturation shift referencing
12	453		(WASSR) for chemical exchange saturation transfer (CEST) experiments. Magn Reson Med.
14 15	454		2009;61(6):1441-1450.
16	455	38.	Vidal A, Gaumet V, Galmier M-J, et al. Development of a freeze-dried kit formulation for the
17 18	456		preparation of 99m Tc-NTP 15-5, a radiotracer for scintigraphic imaging of proteoglycans. Appl
19	457		Radiat Isot. 2015;101:1-9.
20 21	458	39.	Zhou Z, Bez M, Tawackoli W, et al. Quantitative chemical exchange saturation transfer MRI of
22	459		intervertebral disc in a porcine model. Magn Reson Med. 2016;76(6):1677-1683.
23 24	460	40.	Nasrallah FA, Pagès G, Kuchel PW, Golay X, Chuang K-H. Imaging brain deoxyglucose uptake
25 26	461		and metabolism by glucoCEST MRI. J Cereb Blood Flow Metab. 2013;33(8):1270-1278.
20 27	462	41.	Zhou J, Heo H-Y, Knutsson L, van Zijl PCM, Jiang S. APT-Weighted MRI: techniques, current
28 29	463		neuro applications, and challenging issues. J Magn Reson Imaging. 2019;50(2):347-364.
30	464	42.	Oskolkov N, Bar-Shir A, Chan KWY, et al. Biophysical characterization of human protamine-1
31 32	465		as a responsive CEST MR Contrast Agent. ACS Macro Lett. 2015;4(1):34-38.
33	466	43.	Einarsson E, Peterson P, Önnerfjord P, et al. The role of cartilage glycosaminoglycan structure in
34 35	467		gagCEST. NMR Biomed. 2020;33(5):e4259.
36 27	468	44.	Choi HU, Meyer K, Swarm R. Mucopolysaccharide and protein-polysaccharide of a
37 38	469		transplantable rat chondrosarcoma. Proc Natl Acad Sci USA. 1971;68(5):877-879.
39 40	470	45.	Miot-Noirault E, Gouin F, Vidal A, et al. First preclinical imaging of primary cartilage neoplasm
41	471		and its local recurrence using 99mTc-NTP 15-5 radiotracer. J Nucl Med. 2009;50(9):1541-1547.
42 43	472	46.	Walker-Samuel S, Ramasawmy R, Torrealdea F, et al. In vivo imaging of glucose uptake and
44	473		metabolism in tumors. Nat Med. 2013;19(8):1067-1072.
45 46	474	47.	DeBrosse C, Nanga RPR, Bagga P, et al. Lactate Chemical Exchange Saturation Transfer
47 49	475		(LATEST) Imaging in vivo A Biomarker for LDH Activity. Sci Rep. 2016;6:19517.
48 49	476	48.	Chiche J, Brahimi-Horn MC, Pouysségur J. Tumour hypoxia induces a metabolic shift causing
50 51	477		acidosis: a common feature in cancer. J Cell Mol Med. 2010;14(4):771-794.
52	478	49.	Schüre J, Shrestha M, Breuer S, et al. The pH sensitivity of APT-CEST using phosphorus
53 54	479		spectroscopy as a reference method. <i>NMR Biomed</i> . 2019;32(11).
55	480	50.	Wang E, Wu Y, Cheung JS, et al. Mapping tissue pH in an experimental model of acute stroke -
56 57	481		Determination of graded regional tissue pH changes with non-invasive quantitative amide proton
58	482		transfer MRI. Neuroimage. 2019:191:610-617.
59 60			

- 483 483 51. Krikken E, van der Kemp WJM, Khlebnikov V, et al. Contradiction between amide-CEST signal
 484 and pH in breast cancer explained with metabolic MRI. *NMR Biomed*. 2019;32(8).
- 485 52. Schmidt H, Schwenzer NF, Gatidis S, et al. Systematic evaluation of amide proton Chemical
 486 Exchange Saturation Transfer at 3 T: Effects of protein concentration, pH, and acquisition
 487 parameters. *Invest Radiol.* 2016;51(10):635-646.
- 488 53. Liu G, Song X, Chan KWY, McMahon MT. Nuts and bolts of chemical exchange saturation
 489 transfer MRI. *NMR Biomed*. 2013;26(7):810-828.
- 490 54. Zhang X-Y, Wang F, Li H, et al. Accuracy in the quantification of chemical exchange saturation
 491 transfer (CEST) and relayed nuclear Overhauser enhancement (rNOE) saturation transfer effects.
 492 *NMR Biomed.* 2017;30(7):e3716.
 - to pee per per en

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
10	
19 20	
20 21	
21 22	
22	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
30	
20	
30	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51 52	
J۷ 52	
55 54	
55	
56	
57	
58	
59	
60	

494

496

502

495 **FIGURE CAPTIONS**

FIGURE 1: z-spectra of (A) chondroitin 4-sulfate and (C) protamine at several concentrations and pH, 497 respectively. The CEST effects were estimated by measuring the AUC from 0.02 to 1.50 ppm for 498 chondroitin 4-sulfate (GAG CEST) and the signal intensity at 1.96 and 3.60 for guanidyl* and APT* 499 500 CEST, respectively. The relationship between CEST quantification and concentrations or pH are 501 represented on panels (B) and (D), respectively.

503 FIGURE 2: In vivo multimodal imaging of GAGs in SRC bearing mice (A) GAG CEST parametric 504 image. To clearly identify the tumor, the high-resolution image was added inside the inset. (C) SPECT-CT imaging with ^{99m}Tc-NTP 15-5. ROI quantitative analysis of GAG CEST and SPECT-CT are 505 presented in (B) and (D), respectively. (E) Ex vivo tumor slice (X20 magnification) stained with both 506 507 alcian blue and nuclear red. Data were presented by individual values with mean \pm SD. Paired t-test and unpaired t-test (**** P < 0.0001) were applied for in vivo and ex vivo quantifications, respectively. Red 508 data points on panels (B), (D) and (F) correspond to the images shown in (A), (C) and (E), respectively. 509 510 Abbreviations: T: Tumor; M: muscle.

511

519 520

512 FIGURE 3: In vivo multimodal imaging of pH acidification (MRI) and hypoxia (PET) in SRC bearing mice. (A) High resolution and relative variation of APT*/guanidyl* ratio images for 3 representative 513 mice. (B) PET imaging with ¹⁸F-FMISO. ROI quantitative analysis of PET is presented in (C). (D) Ex 514 vivo tumor slice (X20 magnification) stained with pimonidazole and Hoechst. Data were presented by 515 516 individual values with mean \pm SD. Paired t-test (* P = 0.0164) were applied for in vivo quantifications. 517 Red data points on panels (C) correspond to the image shown in (B). Abbreviations: T: Tumor; M: 518 muscle.

3	521	SUPPORTING FIGURE AND TABLE CAPTIONS
4 5	522	
6	523	Supporting Table S1: Overview of the experimental design and analysis by in vivo modality.
/ 8	524	
9	525	Supporting Figure S1: Tumoral volumes measured by MRI at 15-16 days post-induction and presented
10 11	526	as individual values with mean \pm SD. Averaged volume 215.04 \pm 86.28 mm ³
12	527	as martialair talaes that mean = 55.110 taged totalle 210.01 = 00.20 mill :
13 14	528	Supporting Figure S2. Representative data obtained in vivo for a ROI positioned in (blue) the tumor
15	520	and (red) the muscle (A) Mean z spectra for all animals: dotted lines represent ± 1 SD (B) z spectra of
16 17	525	and (red) the muscle. (A) Mean 2-spectra for an animals, dotted mice represent \pm 13D. (B) 2-spectra of
18	530	a representative animal, dotted lines represent the linear baselines applied for guandyl (from 1.66 to 2.20 , 1.4 , 1.6 , 1
19 20	531	2.30 ppm) and APT CEST (from 3.36 to 3.78 ppm) analyses. (C) Lorentzian fit of the GAG CEST from
21	532	the z-spectra shown in (B).
22 23	533	
24	534	Supporting Figure S3: (A) ^{99m} Tc-NTP 15-5 SPECT-CT image of a representative animal. From left to
25 26	535	right: axial slice with tumor, coronal slice with tumor, coronal slice with radiotracer body dispersion
27	536	and sagittal slice with tumor and radiotracer body dispersion. The areas are annotated T for tumor, M
28 29	537	for muscle, B for bladder and Li for liver. (B) ¹⁸ F-FMISO PET image of a representative animal. From
30	538	left to right: axial slice with tumor, coronal and sagittal slices with tumor and radiotracer body
31 32	539	dispersion. The areas were annotated T for tumor, M for muscle, DT for digestive tract. Orientations
33	540	were annotated A for anterior, D for dorsal, L for left, P for posterior, R for right and V for ventral.
34 35		
36 27		
37 38		
39 40		
40 41		
42 42		
43 44		
45 46		
40 47		
48 ⊿q		
5 0		
51 52		
53		
54 55		
56		
57 58		
59		
60		
		17

1		
2 3	541	ABBREVIATIONS
4 5	542	
6	543	APT: Amide proton transfer
/ 8	544	AUC: Area under the curve
9 10	545	BSA: Bovine serum albumin
11	546	CHS: Chondrosarcoma
12 13	547	DMEM: Dulbecco's modified eagle medium
14 15	548	DWI: Diffusion-weighted imaging
15 16	549	ECM: Extracellular matrix
17 18	550	GAG: Glycosaminoglycan
19	551	HRP: Horseradish peroxidase
20 21	552	IVIA: In vivo imaging in Auvergne
22	553	MTC: Magnetization transfer contrast
23 24	554	MTR _{asym} : Magnetization transfer asymmetry
25 26	555	NOE: Nuclear overhauser enhancement
27	556	OSEM: Ordered subset expectation maximization
28 29	557	PBS: Phosphate-buffered saline
30 21	558	PG: Proteoglycan
32	559	RARE: Rapid acquisition with relaxation enhancement
33 34	560	ROI: Region of interest
35	561	SRC: Swarm rat chondrosarcoma
36 37	562	TSA: Tyramide signal amplification
38	563	WASSR: Water saturation shift reference
39 40	564	
41 42	565	
43		
44 45		
46 47		
48		
49 50		
51		
52 53		
54 55		
56		
57 58		



FIGURE 1: z-spectra of (A) chondroitin 4-sulfate and (C) protamine at several concentrations and pH, respectively. The CEST effects were estimated by measuring the AUC from 0.02 to 1.50 ppm for chondroitin 4-sulfate (GAG CEST) and the signal intensity at 1.96 and 3.60 for guanidyl* and APT* CEST, respectively. The relationship between CEST quantification and concentrations or pH are represented on panels (B) and (D), respectively.



FIGURE 2: In vivo multimodal imaging of GAGs in SRC bearing mice (A) GAG CEST parametric image. To clearly identify the tumor, the high-resolution image was added inside the inset. (C) SPECT-CT imaging with 99m Tc-NTP 15-5. ROI quantitative analysis of GAG CEST and SPECT-CT are presented in (B) and (D), respectively. (E) Ex vivo tumor slice (X20 magnification) stained with both alcian blue and nuclear red. Data were presented by individual values with mean \pm SD. Paired t-test and unpaired t-test (**** *P* < 0.0001) were applied for in vivo and ex vivo quantifications, respectively. Red data points on panels (B), (D) and (F) correspond to the images shown in (A), (C) and (E), respectively. Abbreviations: T: Tumor; M: muscle.



FIGURE 3: In vivo multimodal imaging of pH acidification (MRI) and hypoxia (PET) in SRC bearing mice. (A) High resolution and relative variation of APT*/guanidyl* ratio images for 3 representative mice. (B) PET imaging with ¹⁸F-FMISO. ROI quantitative analysis of PET is presented in (C). (D) Ex vivo tumor slice (X20 magnification) stained with pimonidazole and Hoechst. Data were presented by individual values with mean \pm SD. Paired t-test (* *P* = 0.0164) were applied for in vivo quantifications. Red data points on panels (C) correspond to the image shown in (B). Abbreviations: T: Tumor; M: muscle.